Hydroxyethyl starch enhances argatroban-mediated decreases in clot propagation and strength by diminishing thrombin-fibrinogen interactions

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 1, 2007, Pages 49-54

  Nielsen, Vance G ^a   Kirklin, James K ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Kentucky   (United States)

Author keywords

Argatroban; Coagulation; Direct thrombin inhibitors; Hemodilution; Hydroxyethyl starch; Measurement techniques; Thrombelastography

Indexed keywords

ARGATROBAN; FIBRINOGEN; HETASTARCH; PROCOAGULANT; SODIUM CHLORIDE; THROMBIN; THROMBIN INHIBITOR;

ANTICOAGULATION; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; COMBINATION CHEMOTHERAPY; HEMODILUTION; HEMOSTASIS; HUMAN; KINETICS; NONHUMAN; PLASMA; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

ANTICOAGULANTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; DRUG SYNERGISM; FIBRINOGEN; HEMOSTASIS; HEPARIN; HETASTARCH; HUMANS; PIPECOLIC ACIDS; PROTEIN BINDING; THROMBIN; THROMBOCYTOPENIA;

EID: 33845760065     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3280111aa4     Document Type: Article

References (21)

1. Shorten GD, Comunale ME. Heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 1996; 10:521-530.
2. Vender JS, Matthew EB, Silverman IM, Konowitz H, Dau PC. Heparin-associated thrombocytopenia: alternative managements. Anesth Analg 1985; 65:520-522.
3. Longrois D, de Maistre E, Bischoff N, Dopff C, Meistelman C, Angioi M, et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anesth 2000; 47:255-260.
4. Furukawa K, Ohteki H, Hirahara K, Narita Y, Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg 2001; 122:1255-1256.
5. Dyke CM, Koster A, Veale JJ, Maier CW, McNiff T, Levy JH. Preemptive use of Bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg 2005; 80:299-303.
6. Mann MJ, Tseng E, Ratcliffe M, Strattman G, De Silva A, DeMarco T, et al. Use of Bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 2005; 24:222-225.
7. Gasparovic H, Nathan NS, Fitzgerald D, Aranki SF. Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg 2004; 78:e89-e91.
8. Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK. Argatroban, bivalirudin and lepirudin do not decrease clot propagation and strength as effectively as heparin activated antithrombin in vitro. J Heart Lung Transpl 2006; 25:653-663.
9. Nielsen VG. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions. Acta Anaesth Scand 2005; 49:1163-1171.
10. Nielsen VG. Comparison of effects of PentaLyte® and Voluven® hemodilution on plasma clot propagation and strength in the rabbit: role of thrombin-fibrinogen and factor XIII-fibrin interactions. Acta Anaesthesiol Scand 2005; 49:1263-1271.
11. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent 2002; 57:177-184.
12. Kathiseran S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolysis 2002; 13:41-47.
13. Deusch E, Thaler U, Kozek-Langenecker SA. The effects of high molecular weight hydroxyethyl starch solutions on platelets. Anesth Analg 2004; 99:665-669.
14. Thaler U, Deusch E, Kozek-Langenecker SA. In vitro effects of gelatin solutions on platelet function: a comparison with hydroxyethyl starch solutions. Anaesthesia 2005; 60:554-559.
15. De Lorenzo C, Calatzis A, Welsch U, Heindl B. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth Analg 2006; 102:1194-1200.
16. Avorn J, Patel M, Levin R, Winkelmayer WC. Hetastarch and bleeding complications after coronary artery surgery. Chest 2003; 124:1437-1442.
17. Morgan PW, Berridge JC. Giving long-persistent starch as volume replacement can cause pruritus after cardiac surgery. Br J Anaesth 2000; 85:696-699.
18. Kimme P, Jannsen B, Ledin T, Gupta A, Vegfors M. High incidence of pruritus after large doses of hydroxyethyl starch (HES) infusions. Acta Anaesthesiol Scand 2001; 45:686-689.
19. Wiedermann CJ. Hydroxyethyl starch - can the safety problems be ignored? Wien Klin Wochenschr 2004; 116:640-641.
20. Wiedermann CJ. Renal impairment in cardiac surgery patients receiving hydroxyethyl starch. Intensive Care Med 2003; 29:763-769.
21. Wiedermann CJ. Complications of hydroxyethyl starch in acute ischemic stroke and other brain injuries. Patholphysiol Haemost Thromb 2003; 33:225-228.